A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to ...

The prostate cancer diagnostics market size was estimated at USD 9.72 billion in 2025 and is projected to attain around USD 18 billion by 2035, growing at a notable CAGR of 6.36 % from 2026 to 2035.

Prostatic stromal sarcoma (PSS) is a rare malignant mesenchymal tumor originating from the specialized stroma of the prostate. It is a heterogeneous tumor, in which a predominantly phyllodes ...

A nationwide survey of prostate MRI practices in the UK revealed the universal adoption of pre-biopsy MRI across all NHS trusts, with 73.1% using multiparametric MRI protocols. However, significant ...

A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...

In a biopsy, a small sample of tissue is taken from your body. A pathologist analyzes the sample to check for cancer cells. The main method for diagnosing prostate cancer is a core needle biopsy. It’s ...

Objective: This study aimed to investigate independent risk factors for clinically significant prostate cancer (csPCa) using serologic indices, multiparametric magnetic resonance imaging (mpMRI), and ...

Purpose: The accurate diagnosis of prostate cancer (PCa) remains challenging, particularly because standard biopsy techniques do not routinely include anterior zone, leading to potential missed ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

In a retrospective study of 200 biopsy-naïve men, we compared transperineal in-bore MRI-guided biopsies with transrectal MRI-ultrasound fusion biopsies for detecting clinically significant prostate ...